Skip to content

BillionToOne, Inc. BLLN Investment Proceeds

Investment Proceeds at other companies

Natera, Inc. logo
Natera, Inc.NTRA
$0-100%
Incyte logo
IncyteINCY
$0-100%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$79.38M+1,384%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$177.29M+10.4%
TEC
Bio-TechneTECH
$1.09M-95.4%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$302.89M-1.2%

Other financials

Income statement

See full
Revenue$108.4M+83.8%
Gross profit$79.1M+108%
Operating income$17.8M+870%
Net income$18.0M+551%
EPS (diluted)$0.34+187%

Balance sheet

See full
Cash & equivalents$537.5M+181%
Total debt$144.2M
Total equity$505.6M+300%
Total assets$700.7M

Cash flow

See full
Operating cash flow$15.4M+488%
CapEx$4.5M+90.5%
Free cash flow$11.0M+3,842%

Valuation

See full
Market cap$4.8B

Profitability

See full
Gross margin70.4%
Operating margin-96.9%
Net margin8.4%
FCF margin-83.4%

Returns & leverage

See full
Debt / equity0.3×
Current ratio10.9×

Where this comes from

Reported directly by BillionToOne, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments.

The official record: BillionToOne, Inc. ’s 10-K, filed March 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about BillionToOne, Inc. 's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BillionToOne, Inc. 's investment proceeds?
BillionToOne, Inc. (BLLN) reported investment proceeds of $0 in Q4 2025.
What is the long-term trend for BillionToOne, Inc. 's investment proceeds?
Over 2 years (2023 to 2025), BillionToOne, Inc. 's investment proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $90M to $0.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.